|
pubmed:abstractText |
Accumulating evidence indicates that the regimen to increase adiponectin will provide a novel therapeutic strategy for metabolic syndrome. Here, we tested the effect of a potent and selective peroxisome proliferator-activated receptor-? agonist, rivoglitazone (Rivo), a newly synthesized thiazolidinedione derivative, on adiponectin, insulin resistance, and atherosclerosis.
|
|
pubmed:affiliation |
Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
|
